CancerDrs

Prostate Cancer clinical trials in North Carolina

35 actively recruiting prostate cancer trials at 22 sites across North Carolina.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full prostate cancer transparency page →

Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …

Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in North Carolina:
  • Durham VA Medical Center — Durham, North Carolina
  • CarolinaEast Medical Center — New Bern, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in North Carolina:
  • Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
  • Atrium Health University City/LCI-University — Charlotte, North Carolina
  • Levine Cancer Institute-Ballantyne — Charlotte, North Carolina
  • Wake Forest University at Clemmons — Clemmons, North Carolina
  • Atrium Health Cabarrus/LCI-Concord — Concord, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in North Carolina:
  • Durham VA Medical Center — Durham, North Carolina
  • Duke University Medical Center — Durham, North Carolina
  • FirstHealth of the Carolinas-Moore Regional Hospital — Pinehurst, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or dea…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in North Carolina:
  • Duke University Medical Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. Th…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05939414
Sites in North Carolina:
  • East Carolina University — Greenville, North Carolina
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Federal

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…

Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in North Carolina:
  • Durham VA Medical Center, Durham, NC — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in North Carolina:
  • Duke University — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC …

Sponsor: Kyntra Bio
NCT ID: NCT06842498
Sites in North Carolina:
  • Duke University Medical Center - Duke Cancer Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use ola…

Sponsor: VA Office of Research and Development
NCT ID: NCT04038502
Sites in North Carolina:
  • Durham VA Medical Center, Durham, NC — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therap…

Sponsor: VA Office of Research and Development
NCT ID: NCT05011383
Sites in North Carolina:
  • Durham VA Medical Center, Durham, NC — Durham, North Carolina
  • Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC — Salisbury, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06800313
Sites in North Carolina:
  • Duke University Medical Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on…

Sponsor: Zenith Epigenetics
NCT ID: NCT04986423
Sites in North Carolina:
  • Messino Cancer Center — Asheville, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer

This study is researching an investigational drug called REGN4336 both alone or together with another investigational drug called REGN5678. The study is focused on participants with previously treated metastatic prostate cancer. The main p…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT05125016
Sites in North Carolina:
  • Atrium Health Levine Cancer Institute — Charlotte, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have successfully estimated g values that accurat…

Sponsor: Sun Pharmaceutical Industries Limited
NCT ID: NCT05422911
Sites in North Carolina:
  • W.G. Bill Hefner Medical Center — Salisbury, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

This is a four-part study evaluating the safety and efficacy of a PSMA-directed radioantibody (rosopatamab tetraxetan, conjugated to either In-111 or Ac-225). Part 1 will consist of one administration of In-111-rosopatamab tetraxetan to ch…

Sponsor: Convergent Therapeutics
NCT ID: NCT06549465
Sites in North Carolina:
  • Duke University Medical Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed prior therapy with androgen receptor pathway inhibitors.

Sponsor: Syntrix Biosystems, Inc.
NCT ID: NCT06228053
Sites in North Carolina:
  • Duke University — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

This phase II randomized control trial assesses the effect of Urolithin A (Uro-A) supplementation compared to placebo in men with biopsy-confirmed prostate cancer undergoing radical prostatectomy (RP) progressive disease. A total of 90 men…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06022822
Sites in North Carolina:
  • Duke University Medical Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of DM002 in Patients With Advanced Solid Tumors

The goal of study： The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling…

Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
NCT ID: NCT06751329
Sites in North Carolina:
  • Carolina BioOncology Institute, LLC — Huntersville, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer

The purpose of this research study is to find out what effects (good and bad) omeprazole and cabazitaxel, or omeprazole and docetaxel, has on participants and their condition. Investigators believe omeprazole may help the other medications…

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT04337580
Sites in North Carolina:
  • W.G. Bill Hefner VA Medical Center — Salisbury, North Carolina
  • Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amen…

Sponsor: Amgen
NCT ID: NCT04221542
Sites in North Carolina:
  • Duke University Medical Center — Durham, North Carolina
  • Wake Forest University Health Sciences — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with adv…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT04729114
Sites in North Carolina:
  • Duke Cancer Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of t…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06095089
Sites in North Carolina:
  • Atrium Health Levine Cancer Institute — Charlotte, North Carolina
View on ClinicalTrials.gov →

Showing 25 of 35 trials with sites in North Carolina. See all prostate cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-01